Strides Arcolab has got the green signal for an anti-bacterial drug, Polymyxin Injection which is USD 8 million drugs from the US FDA.

Arun Kumar, Vice Chairman and MD, Strides Arcolab, in an interview with CNBC-TV18 revealed that the Polymyxin is very small molecule and is in deficiency list of products which only the few drug makers are supplying.

He asserted that during the current year, the company will grow by 30-35%.

In an interview with Latha Venkatesh and Sonia Shenoy of CNBC-TV18, when asked about the company’s plan for the facility in Malaysia, he replied that the Malaysian Biotech Ecosystem will be setting up the plant which will be used by the Strides Arcolab on lease basis thus avoiding capital investment in the country and it will take around three years to get the output from the Malaysian facility.

During the current interview, he was asked about the capacity constraints which he had mentioned in the last interview for which he replied that capacity constraints are not related to the company’s Oncology business but are related to non oncology business. At present the company is having 35 non oncology products in the market.

Strides Arcolab revealed that Banglore based Onco Therapies Ltd (OTL), a division of Agila which is completely owned subsidiary, has bagged the USFDA approval for the oral medicine.

Mr. Venkat Iyer, the Agila Specialties CEO, said, “The approval is also a testimony to the high standards of quality, compliance and containment practices put in place by Strides.”

This is the third product which has got the approval for Sagent Strides LLC in 2011 under the Sagent-Strides jointventure.

The share of the company has touched Rs 477.75 which is 52 week high.